Here are three things to know:
1. For the study, researchers used randomized controlled trials to compare the immunogenicity and safety of double-dose and standard dose flu vaccines in 63 kidney and 16 liver transplant recipients. Forty patients received the double-dose flu vaccine and 39 received the single-dose vaccine.
2. Forty percent of the double-dose patients responded to the vaccine, compared to the 26 percent of the single-dose patients. In the double-dose group, 88 percent were protected against all viral strains, compared to 69 percent of people in the single-dose group. About 132 titers of antibodies for the H1Ni virus were present in the double-dose group post-vaccination, compared to about 90 titers of antibodies in the single-dose group.
3. Researchers concluded the double-dose influenza vaccine is safe for patients with compromised immune systems and may increase antibody response in transplant recipients.
More articles on clinical leadership and infection control:
Older, sicker patients often uncomfortable speaking up about problems during hospital stays, survey finds
Chan Zuckerberg Initiative, Bill & Melinda Gates Foundation partner to detect infectious disease spread
The Joint Commission appoints co-directors of Standards Interpretation Group
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
